|
Why a new initiative for HIV
prevention?
An estimated 40,000 new HIV
infections still occur in the United
States each year. An estimated one
quarter of the 850,000 to 950,000 people
living with HIV in the United States do
not yet know they are infected.1
In addition, data from several studies
have shown increases in syphilis
diagnoses among men who know that they
are infected with HIV, suggesting
increases in risk behaviors among people
living with HIV and their partners.2,3,4,5
How does
the Advancing HIV Prevention initiative
address this problem?
This initiative consists of the
following 4 strategies aimed at reducing
barriers to diagnosis of HIV infection
and access to and use of quality medical
care, treatment, and ongoing prevention
services for persons with HIV.
- Make HIV testing a routine part of
medical care whenever and wherever
patients go for care.
- Use new models for diagnosing HIV
infection outside of traditional
medical settings.
- Prevent new infections by working
with people diagnosed with HIV and
their partners.
- Continue to decrease
mother-to-child HIV transmission.
How will
increasing HIV testing help to reduce
HIV infections?
There are many benefits to early
knowledge of HIV infection, including
early entry into treatment to prevent
illnesses that arise from a weakened
immune system, treatment of other
conditions like substance abuse and
sexually transmitted diseases, and
access to social services and medical
treatments, when appropriate.6
HIV-infected persons in care are now
living longer than before thanks to new
highly effective treatments.7
In addition to these personal
benefits, knowledge of one’s HIV
infection can help prevent spread of the
infection to others. When people know
that they are infected with HIV, they
are significantly more likely to protect
their partners from infection than when
they were unaware of their infection.8,9,10,11
About 40% of HIV-infected persons
first find out that they have HIV less
than 1 year before AIDS diagnosis.12
On average, it takes 10 years after HIV
infection for symptoms of AIDS to
appear. People who have their first HIV
test close to getting an AIDS diagnosis
have been infected and not known it,
possibly for many years, potentially
passing the infection to their partners.
Early diagnosis of HIV enables infected
persons and those close to them to take
steps to prevent transmission.13,14
If a person with HIV is tested,
learns of his or her status, and has
access to appropriate treatments, the
amount of virus in the body can be
reduced, which may decrease the risk for
transmission to partners.15
This reduction of HIV transmission is
most clearly seen in reducing
transmission of HIV from mother to child
by treating pregnant women who are HIV
positive.16,17,18,19
Why these
4 strategies?
Make HIV testing a routine
part of medical care
Routine voluntary
screening for disease is a basic and
effective public health tool used to
identify unrecognized medical conditions
so that treatment and other services can
be offered.20,21 HIV
screening meets the three generally
accepted principles that apply to
screening efforts:
- It is a serious disease that can
be detected before symptoms occur
using a reliable and inexpensive test.
- Treatment given before symptoms
develop is more effective than waiting
until after symptoms develop.22,23,24
- Cost of screening is reasonable
compared with anticipated benefits.25,26,27
Screening all persons in
high-prevalence medical settings,
regardless of what if any HIV risks are
reported, makes sense because testing
based on reported or perceived risk
alone fails to identify many
HIV-infected persons.28
Acceptance of HIV testing, as
demonstrated among pregnant women, is
greater when it is offered routinely
than when it is based on risk
assessments.20
Use
new models for diagnosing HIV infection
outside of traditional medical settings
HIV testing programs outside of
traditional medical settings are more
likely to reach some racial/ethnic
minorities and persons who report
increased risk for HIV but do not have
access to medical care.29 In
addition, the rate of positive test
results in non-traditional settings is
generally higher compared with
conventional testing sites.29
For
example, it has been estimated that
nearly 25% of persons living with HIV
pass through the corrections system,30
yet fewer than half of these systems
routinely test inmates at entry.31
This means that many HIV-infected
persons miss out on the opportunity to
be routinely screened
Recently
approved rapid HIV tests can be done
outside a traditional laboratory setting
and can reduce the time it takes to
process tests from 2 weeks to 20
minutes.32 The availability
of these tests means testing can be
implemented in diverse settings and
essential health information can be
provided quickly in settings where
people may be unlikely to return to
receive test results. These tests
provide opportunities to dramatically
increase the number of people who know
their HIV status.33,34
Prevent
new infections by working with people
diagnosed with HIV and their partners
Each person living with HIV who adopts
safer behavior can prevent many
transmissions of HIV infection. There is
much evidence that upon learning one is
HIV-positive, infected persons reduce
their risk behaviors and the likelihood
of transmitting HIV to partners.8,9,10,11
Among persons testing positive for HIV,
there was a 70% reduction in reported
risk behavior at 1 year after diagnosis.35
Among persons testing negative for HIV,
those receiving enhanced risk reduction
counseling had only 18% fewer sexually
transmitted infections at 1 year after
testing compared with persons receiving
standard counseling.36 These
studies suggest that working with
HIV-infected persons will result in
greater reductions in risk behaviors and
HIV transmission than working with
HIV-negative persons.
In
studies of partner counseling and
referral services, researchers found
that 8% - 39% of partners of persons
with HIV infection who were tested were
found to have previously undiagnosed HIV
infection.37,38 Because of
this finding, CDC will increase emphasis
on assisting HIV-infected persons in
notifying partners of their recent
exposure and ensure voluntary testing of
partners.
Prevention
interventions including ongoing case
management, focused risk-reduction
counseling, medical interventions, and
support for other psychosocial
stressors, are recommended under this
initiative to help HIV-positive persons
maintain protective behaviors.39,40,41,42,43
Continue
to decrease perinatal HIV transmission.
Each year approximately 6,000-7,000
women with HIV give birth resulting in
more than 300 HIV-infected infants. The
use of appropriate anti-HIV medications
that begins during pregnancy,16
together with other obstetric
interventions can maximally reduce the
risk for mother-to-child transmission to
less then 2%.
Efforts
are underway to eliminate perinatal HIV
transmission in the United States and
the CDC currently recommends that all
pregnant women be screened for HIV in
order to take advantage of the medical
interventions that dramatically reduce
the risk for transmission.44
CDC strongly supports the “opt-out”
testing strategy for prenatal HIV
screening on the same voluntary basis as
other tests.45 Making HIV
screening part of the standard battery
of tests for pregnant women sets the
stage for continued prevention and
furthers efforts to eliminate perinatal
HIV transmission in the United States.20
Implementation
of initiative activities
Implementation
of the new initiative requires strong
and extensive partnerships with
cooperation and coordination among CDC,
the public health community, and the
medical care community. With the support
of the Department of Health and Human
Services, CDC and its partners,
including other federal agencies, state
and local health departments,
community-based organizations, and
professional organizations will
implement these activities and
reenergize our efforts to meet the
challenges of this changing epidemic.
1
Fleming P, Byers RH, Sweeney PA, Daniels
D, Karon JM, Janssen RS. HIV prevalence
in the United States, 2000 [Abstract].
In: Program and abstracts of the 9th
Conference on Retroviruses and
Opportunistic Infections; Seattle,
Washington; February 24-28, 2002.
2
CDC. Primary and secondary syphilis
among men who have sex with men—New
York City, 2001. MMWR. 2002;51:853–6
3
CDC. Resurgent bacterial sexually
transmitted disease among men who have
sex with men—King County, Washington,
1997–1999. MMWR. 1999;48:773–7
4
Ciesielski C, Beidinger H. Emergence of
primary and secondary syphilis among men
who have sex with men in Chicago and
relationship to HIV infection. In:
Program and abstracts of the 7th
Conference on Retroviruses and
Opportunistic Infections; Chicago,
Illinois; January 30–February 2, 2000.
Abstract 470.
5
CDC. Outbreak of syphilis among men who
have sex with men—Southern California,
2000. MMWR 2001;50:117–20.
6
Department of Health and Human Services.
Guidelines for the use of antiretroviral
agents in HIV-infected adults and
adolescents. The living document:
February 4, 2004. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_020402.pdf.
Accessed June 4, 2003.
7
The CASCADE Collaboration. Survival
after introduction of HAART in people
with known duration of HIV-1 infection.
Lancet. 2000;355:1158–59.
8
Wenger NS, Kussling FS, Beck K, Shapiro
MF. Sexual behavior of individuals
infected with the human immunodeficiency
virus: The need for intervention. Arch
Int Med 1994:154:1849–54.
9
Kilmarx PH, Hamers FF, Peterman TA.
Living with HIV: Experiences and
perspectives of HIV-infected sexually
transmitted disease clinic patients
after posttest counseling. Sex Transm
Dis. 1998:25:28-37.
10
Higgins DL, Galavotti C, O’Reilly KE,
et al. Evidence for the effects of HIV
antibody counseling and testing on risk
behaviors. JAMA. 1991;266:2419–29.
11
Hays RB, Paul J, Ekstrand M, Kegeles SM,
Stall R, Coates TJ. Actual versus
perceived HIV status, sexual behaviors
and predictors of unprotected sex among
young gay and bisexual men who identify
as HIV-negative, HIV-positive and
untested. AIDS. 1997;11:1495–1502.
12
Neal JJ, Fleming PL. Frequency and
predictors of late HIV diagnosis in the
United States, 1994 through 1999
[Abstract 474M]. 9th Conference on
Retroviruses and Opportunistic
Infections, Seattle, February 24-28,
2002.
13
Janssen RS, Holtgrave DR, Valdiserri RO,
Shepherd M, Gayle HD, DeCock KM. The
serostatus approach to fighting the HIV
epidemic: prevention strategies for
infected individuals. Am J Public
Health. 2001;91:1019–24.
14
Institute of Medicine. No time to lose:
getting more from HIV prevention.
Washington, DC: National Academy Press,
2001.
15
Quinn TC, Wawer MJ, Sewankambo N, et al.
Viral load and heterosexual transmission
of human immunodeficiency virus type 1.
N Engl J Med 2000;342:921–9.
16
Connor EM, Sperling RS, Gelber R, et al.
Reduction of maternal-infant
transmission of human immunodeficiency
virus type 1 with zidovudine treatment.
N Engl J Med. 1994;331:1173–80.
17
Shaffer N, Chuachoowong R, Mock PA, et
al. Short course zidovudine for
perinatal HIV-transmission in Bangkok,
Thailand: A randomized controlled trial.
Lancet. 1999;353:773–80.
18
Morris A, Zorrilla C, Vajaranant M, et
al. A review of protease inhibitor use
in 89 pregnancies [Abstract]. In:
Program and abstracts of the 6th
Conference on Retroviruses and
Opportunistic Infections; Chicago,
Illinois; January 31 – February 4,
1999. Alexandria, Virginia: Foundation
for Retrovirology and Human Health.
19
Peters V, Marinovich A, Singh T,
Lindegren ML, Bertolli J, Thomas P.
Trends to reduce perintal HIV
transmission in New York City
[Abstract]. In: Program and Abstracts of
the 7th Conference on Retroviruses and
Opportunistic Infections; San Francisco,
California; January 30 – February 2,
2000. Alexandria, Virginia: Foundation
for Retrovirology and Human Health.
20
Institute of Medicine, National Research
Council. Reducing the odds: Preventing
perinatal transmission of HIV in the
United States. Washington DC: National
Academy Press, 1999.
21
Last JM. A dictionary of epidemiology,
3d Edition. New York: Oxford University
Press, 1995.
22
Palella FJ, Deloria-Knoll M, Chmiel JS,
Moorman AC, Wood KC, et al. Survival
benefit of initiating antiretroviral
therapy in HIV-infected persons in
different CD4+ cell strata. Ann Intern
Med. 2003;138:620–6.
23
Hogg RS, Yip B, Chan KJ, Wood E, Craib
KJ, O’Shaughnessy MV, et al. Rates of
disease progression by baseline CD4 cell
count and viral load after initiating
triple-drug therapy. JAMA
2001;286:2568–77.
24
Opravil M, Ledergerber B, Furrer H,
Hirschel B, Imhof A, Gallant S, et al.
Clinical efficacy of early initiation of
HAART in patients with asymptomatic HIV
infection and CD4 cell count >350 x
10(6)/l. AIDS. 2002;16:1371–81.
25
Wilson JM, Junger CT. Principles and
practice of screening for disease. World
Health Organization Public Health Paper
34; 1968.
26
Freedberg LA. Samet JH. Think HIV: Why
physicians should lower their threshold
for HIV testing. Arch Intern Med.
1999;159:1994–2000.
27
Walensky RP, Weinstein MC, Kimmel AD,
Seage III GR, Losina E, Sax PE, et al.
Routine inpatient HIV testing: A
clinical and economic evaluation of
national guidelines. National HIV
Prevention Conference; Atlanta, GA; July
2003. Abstract T3-E1102.
28
Walensky RP, Losina E, Steger-Craven KA,
Freedberg KA. Identifying undiagnosed
human immunodeficiency virus: The yield
of routine, voluntary inpatient testing.
Arch Intern Med. 2002;162:887–92.
29
Greby S, Frey B, Royalty J, et al. Use
of simple oral fluid HIV-tests in
CDC-funded facilities. In: Program and
abstracts of XIV International
Conference on AIDS; Barcelona, Spain;
July 2002. Abstract TuPeD4991.
30
Spaulding A, Stephenson B, Macalino G,
Ruby W, Clarke JG, Flanigan TP. Human
immunodeficiency virus in correctional
facilities: A review. Clin Infect Dis.
2002;35:305–12.
31
Hammett TH, Harmon P, Maruschak LM.
1996-1997 update: HIV/AIDS, STDs, and TB
in correctional facilities. Washington
DC: US Department of Justice, National
Institute of Justice.
32
CDC. Notice to readers: Approval
of a new rapid test for HIV antibody.
MMWR. 2002:51:1051–52.
33
Kassler WJ, Dillon GA, Haley C, et at.
On-site, rapid HIV testing with same-day
results and counseling. AIDS.
1997;11:1045–51.
34
Horton T, Uniyal A, Smith LV, Curreri S,
Kerndt P, Branson B. Feasibility of
implementing rapid HIV testing in a
community-based setting. National HIV
Prevention Conference; Atlanta GA; July
2003. Abstract T2-C1503.
35
Colfax GN, Buchbinder SP, Cornelisse PGA,
et al. Sexual risk behaviors and
implications for secondary HIV
transmission during and after HIV
seroconversion. AIDS. 2002;16:1529–35.
36
Kamb ML, Fishbein, M, Douglas JM, et al.
Efficacy of risk-reduction counseling to
prevent human immunodeficiency virus and
sexually transmitted diseases: A
randomized controlled trial
JAMA . 1998;280:1161–67.
37
Golden MR. HIV partner notification: a
neglected prevention intervention
[editorial]. Sex Transm Dis.
2002;29:472–5.
38
Jordan WC, Tolbert L, Smith R. Partner
notification and focused intervention as
a means of identifying HIV-positive
patients. J Natl Med Assoc.
1998;90:542–6.
39
Kalichman SC, Rompa D. HIV treatment
adherence and unprotected sex practices
in people receiving antiretroviral
therapy. Sex Transm Infect.
2003;79:59–61.
40
Schreibman T, Friedland G. Human
immunodeficiency virus infection
prevention: Strategies for Clinicians.
Clin Infect Dis. 2003;36:1171–76.
41
CDC. HIV prevention case management:
Guidance. Centers for Disease Control
and Prevention: Atlanta, Georgia; 1997.
(Available at: www.cdc.gov/hiv
)
42
Rotheram-Borus M, Kelly JA, Ehrhardt AA,
Chesney MA, Lightfoot M, Weinhardt LS,
et al. HIV transmission risk behavior,
medication adherence, mental health ,
and substance use in a four-city sample
of people living with HIV: Implications
for HIV prevention—findings from the
NIMH Healthy Living Project. National
HIV Prevention Conference; Atlanta, GA;
July 2003. Abstract T1-F0403.
43
Mizuno Y, Moore J, Rompaolo A, Shoenbaum
E, Schuman P, Mayer K, et al. Competing
life concerns and condom use among
HIV-infected women. National HIV
Prevention Conference; Atlanta, GA; July
2003. Abstract TOP-005.
44
CDC. Revised recommendations for HIV
screening of pregnant women. MMWR.
2001;50(RR No. 19):50–86.
45
CDC. HIV Testing among pregnant women
--- United States and Canada, 1998 -
2001. MMWR.2002;51(45):1013-16. |